IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Modern Wealth Management LLC

Modern Wealth Management LLC decreased its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 22.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,093 shares of the medical research company’s stock after selling 312 shares during the quarter. Modern Wealth Management LLC’s holdings in IQVIA were worth $226,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of IQV. Synergy Asset Management LLC acquired a new position in IQVIA during the 4th quarter valued at about $33,000. Lee Danner & Bass Inc. acquired a new position in shares of IQVIA during the fourth quarter worth approximately $44,000. Versant Capital Management Inc grew its holdings in IQVIA by 46.0% in the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock worth $58,000 after buying an additional 93 shares in the last quarter. SBI Securities Co. Ltd. acquired a new stake in IQVIA in the 4th quarter valued at approximately $60,000. Finally, UMB Bank n.a. raised its stake in IQVIA by 72.8% during the 4th quarter. UMB Bank n.a. now owns 401 shares of the medical research company’s stock valued at $79,000 after acquiring an additional 169 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently issued reports on IQV. Stifel Nicolaus decreased their price target on IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Robert W. Baird lowered their target price on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 21st. Citigroup dropped their price target on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Truist Financial reiterated a “buy” rating and set a $263.00 price objective (up previously from $261.00) on shares of IQVIA in a research note on Monday, February 10th. Finally, UBS Group cut their target price on IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Five equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $249.05.

IQVIA Stock Performance

Shares of IQV opened at $177.27 on Friday. The company has a 50-day moving average of $193.15 and a two-hundred day moving average of $206.47. The stock has a market cap of $31.25 billion, a price-to-earnings ratio of 23.64, a PEG ratio of 1.99 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a one year low of $176.03 and a one year high of $253.84.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.